| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hospitals, Veterans | 36 | 2021 | 364 | 5.190 |
Why?
|
| Patient Protection and Affordable Care Act | 10 | 2024 | 66 | 5.140 |
Why?
|
| Medicaid | 10 | 2024 | 254 | 4.670 |
Why?
|
| United States Department of Veterans Affairs | 43 | 2024 | 707 | 4.480 |
Why?
|
| Reimbursement, Incentive | 14 | 2018 | 48 | 4.210 |
Why?
|
| Quality of Health Care | 22 | 2022 | 421 | 3.820 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 29 | 2023 | 757 | 3.420 |
Why?
|
| Veterans | 30 | 2024 | 1779 | 3.040 |
Why?
|
| Cardiovascular Diseases | 32 | 2023 | 2091 | 2.960 |
Why?
|
| Primary Health Care | 22 | 2022 | 803 | 2.930 |
Why?
|
| United States | 113 | 2024 | 11718 | 2.720 |
Why?
|
| Veterans Health | 10 | 2023 | 179 | 2.700 |
Why?
|
| Quality Indicators, Health Care | 12 | 2024 | 232 | 2.590 |
Why?
|
| Delivery of Health Care | 15 | 2023 | 678 | 2.500 |
Why?
|
| Nursing Staff, Hospital | 4 | 2024 | 67 | 2.490 |
Why?
|
| Hypertension | 19 | 2021 | 1397 | 2.430 |
Why?
|
| Quality Assurance, Health Care | 7 | 2021 | 222 | 2.360 |
Why?
|
| Atherosclerosis | 20 | 2023 | 999 | 2.170 |
Why?
|
| Cholesterol, LDL | 13 | 2021 | 604 | 2.030 |
Why?
|
| Hospitals | 8 | 2024 | 436 | 1.980 |
Why?
|
| Health Services Research | 19 | 2020 | 191 | 1.870 |
Why?
|
| Medical Records Systems, Computerized | 11 | 2010 | 172 | 1.820 |
Why?
|
| Guideline Adherence | 20 | 2019 | 400 | 1.800 |
Why?
|
| Patient Care Team | 9 | 2019 | 573 | 1.770 |
Why?
|
| Workload | 3 | 2024 | 151 | 1.600 |
Why?
|
| Politics | 3 | 2023 | 61 | 1.590 |
Why?
|
| Cancer Survivors | 10 | 2025 | 247 | 1.560 |
Why?
|
| Ambulatory Care | 7 | 2022 | 415 | 1.560 |
Why?
|
| Physicians | 6 | 2017 | 635 | 1.520 |
Why?
|
| Diabetes Mellitus | 15 | 2021 | 936 | 1.520 |
Why?
|
| Humans | 219 | 2025 | 133775 | 1.490 |
Why?
|
| Coronary Disease | 9 | 2020 | 721 | 1.450 |
Why?
|
| Health Services Accessibility | 16 | 2023 | 648 | 1.430 |
Why?
|
| Personnel Staffing and Scheduling | 5 | 2024 | 83 | 1.420 |
Why?
|
| Intensive Care Units, Neonatal | 8 | 2014 | 330 | 1.310 |
Why?
|
| Aged | 90 | 2025 | 21691 | 1.280 |
Why?
|
| Physician Incentive Plans | 5 | 2017 | 13 | 1.280 |
Why?
|
| Practice Patterns, Physicians' | 17 | 2020 | 770 | 1.270 |
Why?
|
| Nurse Practitioners | 4 | 2021 | 50 | 1.250 |
Why?
|
| Middle Aged | 92 | 2025 | 29318 | 1.240 |
Why?
|
| Physician Assistants | 4 | 2021 | 71 | 1.220 |
Why?
|
| Patient Acceptance of Health Care | 6 | 2020 | 474 | 1.210 |
Why?
|
| Coronary Artery Disease | 9 | 2022 | 889 | 1.210 |
Why?
|
| Insurance Coverage | 4 | 2024 | 124 | 1.160 |
Why?
|
| Physicians, Primary Care | 6 | 2021 | 98 | 1.140 |
Why?
|
| Risk Adjustment | 7 | 2021 | 60 | 1.100 |
Why?
|
| Hypolipidemic Agents | 4 | 2019 | 187 | 1.090 |
Why?
|
| Male | 117 | 2024 | 65895 | 1.090 |
Why?
|
| Breast Neoplasms | 14 | 2025 | 2768 | 1.090 |
Why?
|
| Female | 119 | 2025 | 71655 | 1.080 |
Why?
|
| Medicare | 10 | 2023 | 463 | 1.060 |
Why?
|
| Diagnostic Errors | 7 | 2011 | 347 | 1.040 |
Why?
|
| Lipids | 6 | 2019 | 566 | 1.010 |
Why?
|
| Myocardial Infarction | 12 | 2020 | 1102 | 1.010 |
Why?
|
| State Government | 2 | 2023 | 30 | 1.000 |
Why?
|
| Quality Improvement | 8 | 2024 | 695 | 1.000 |
Why?
|
| Outpatient Clinics, Hospital | 5 | 2013 | 77 | 0.930 |
Why?
|
| Continuity of Patient Care | 6 | 2018 | 153 | 0.920 |
Why?
|
| Cholesterol | 9 | 2019 | 574 | 0.880 |
Why?
|
| Practice Guidelines as Topic | 16 | 2019 | 1338 | 0.880 |
Why?
|
| Nursing Research | 1 | 2024 | 14 | 0.860 |
Why?
|
| Infant, Very Low Birth Weight | 4 | 2014 | 178 | 0.850 |
Why?
|
| Logistic Models | 18 | 2020 | 1908 | 0.830 |
Why?
|
| Poverty | 3 | 2024 | 437 | 0.830 |
Why?
|
| Mindfulness | 4 | 2024 | 26 | 0.830 |
Why?
|
| Peer Review, Health Care | 2 | 2013 | 17 | 0.800 |
Why?
|
| Dyslipidemias | 7 | 2020 | 244 | 0.790 |
Why?
|
| User-Computer Interface | 2 | 2023 | 167 | 0.790 |
Why?
|
| Hypercholesterolemia | 6 | 2019 | 236 | 0.780 |
Why?
|
| Research Design | 4 | 2021 | 747 | 0.770 |
Why?
|
| Mortality | 4 | 2008 | 262 | 0.770 |
Why?
|
| Hospital Mortality | 6 | 2023 | 1090 | 0.750 |
Why?
|
| Eligibility Determination | 4 | 2022 | 38 | 0.730 |
Why?
|
| Health Insurance Exchanges | 1 | 2021 | 3 | 0.730 |
Why?
|
| Decision Support Techniques | 3 | 2023 | 320 | 0.720 |
Why?
|
| Diagnosis-Related Groups | 4 | 2010 | 28 | 0.720 |
Why?
|
| Cross-Sectional Studies | 19 | 2023 | 3743 | 0.720 |
Why?
|
| Perioperative Period | 1 | 2021 | 53 | 0.710 |
Why?
|
| Healthcare Disparities | 8 | 2021 | 478 | 0.700 |
Why?
|
| National Health Insurance, United States | 1 | 2020 | 3 | 0.690 |
Why?
|
| Fatigue | 6 | 2024 | 203 | 0.690 |
Why?
|
| Colonoscopy | 4 | 2023 | 249 | 0.680 |
Why?
|
| Drug Prescriptions | 8 | 2020 | 238 | 0.670 |
Why?
|
| Sex Factors | 10 | 2024 | 1387 | 0.670 |
Why?
|
| Surgical Procedures, Operative | 2 | 2021 | 190 | 0.670 |
Why?
|
| Health Care Reform | 1 | 2020 | 52 | 0.670 |
Why?
|
| Employment | 2 | 2020 | 71 | 0.650 |
Why?
|
| Depression | 10 | 2024 | 1359 | 0.640 |
Why?
|
| Work Performance | 1 | 2019 | 14 | 0.610 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2021 | 284 | 0.610 |
Why?
|
| Adult | 50 | 2025 | 31894 | 0.610 |
Why?
|
| Attitude of Health Personnel | 9 | 2020 | 716 | 0.610 |
Why?
|
| Communication | 6 | 2020 | 542 | 0.600 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 53 | 0.590 |
Why?
|
| Motivation | 3 | 2019 | 328 | 0.590 |
Why?
|
| Hospital Costs | 5 | 2007 | 187 | 0.590 |
Why?
|
| Ambulatory Care Facilities | 4 | 2016 | 239 | 0.580 |
Why?
|
| Aspirin | 6 | 2020 | 231 | 0.570 |
Why?
|
| Registries | 11 | 2021 | 1571 | 0.560 |
Why?
|
| Reminder Systems | 2 | 2009 | 65 | 0.560 |
Why?
|
| Cardiology | 7 | 2019 | 521 | 0.560 |
Why?
|
| Fee-for-Service Plans | 4 | 2009 | 19 | 0.560 |
Why?
|
| Patient-Centered Care | 3 | 2019 | 237 | 0.550 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2016 | 904 | 0.550 |
Why?
|
| Myocardial Ischemia | 9 | 2021 | 365 | 0.540 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2023 | 1415 | 0.530 |
Why?
|
| Referral and Consultation | 3 | 2010 | 571 | 0.530 |
Why?
|
| Medication Adherence | 7 | 2021 | 342 | 0.530 |
Why?
|
| Decision Support Systems, Clinical | 4 | 2023 | 200 | 0.520 |
Why?
|
| Cardiac Catheterization | 6 | 2007 | 667 | 0.520 |
Why?
|
| Retrospective Studies | 27 | 2024 | 17433 | 0.520 |
Why?
|
| Intensive Care, Neonatal | 2 | 2014 | 57 | 0.500 |
Why?
|
| Diffusion of Innovation | 2 | 2009 | 99 | 0.500 |
Why?
|
| Diagnostic Imaging | 2 | 2009 | 317 | 0.490 |
Why?
|
| Interprofessional Relations | 2 | 2014 | 156 | 0.480 |
Why?
|
| Anticholesteremic Agents | 5 | 2019 | 245 | 0.470 |
Why?
|
| Electronic Health Records | 5 | 2024 | 795 | 0.470 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 1154 | 0.470 |
Why?
|
| Risk Assessment | 11 | 2021 | 3713 | 0.460 |
Why?
|
| American Heart Association | 4 | 2019 | 329 | 0.460 |
Why?
|
| Colorectal Neoplasms | 6 | 2016 | 650 | 0.450 |
Why?
|
| Peripheral Arterial Disease | 5 | 2020 | 313 | 0.440 |
Why?
|
| Research Report | 1 | 2014 | 78 | 0.440 |
Why?
|
| Models, Statistical | 6 | 2018 | 505 | 0.440 |
Why?
|
| Age Factors | 10 | 2021 | 2990 | 0.440 |
Why?
|
| Blood Pressure | 7 | 2019 | 1420 | 0.440 |
Why?
|
| Diabetes Complications | 2 | 2016 | 206 | 0.440 |
Why?
|
| Clinical Competence | 7 | 2019 | 1059 | 0.430 |
Why?
|
| Health Services | 3 | 2008 | 73 | 0.420 |
Why?
|
| Publishing | 1 | 2014 | 115 | 0.420 |
Why?
|
| Health Personnel | 2 | 2018 | 541 | 0.410 |
Why?
|
| Safety Management | 4 | 2012 | 121 | 0.410 |
Why?
|
| Attitude to Health | 2 | 2005 | 262 | 0.410 |
Why?
|
| Cooperative Behavior | 4 | 2020 | 232 | 0.410 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2013 | 35 | 0.410 |
Why?
|
| Meditation | 2 | 2024 | 19 | 0.400 |
Why?
|
| Data Collection | 6 | 2023 | 398 | 0.400 |
Why?
|
| Nursing Homes | 1 | 2013 | 107 | 0.400 |
Why?
|
| Dissent and Disputes | 2 | 2023 | 32 | 0.390 |
Why?
|
| Program Evaluation | 2 | 2015 | 453 | 0.390 |
Why?
|
| Secondary Prevention | 4 | 2022 | 225 | 0.390 |
Why?
|
| Occult Blood | 2 | 2009 | 32 | 0.390 |
Why?
|
| Problem Solving | 1 | 2012 | 67 | 0.390 |
Why?
|
| Ethics Committees, Research | 1 | 2012 | 33 | 0.380 |
Why?
|
| Primary Prevention | 4 | 2023 | 179 | 0.370 |
Why?
|
| Aged, 80 and over | 18 | 2020 | 7200 | 0.370 |
Why?
|
| Databases, Factual | 7 | 2017 | 1243 | 0.370 |
Why?
|
| Medical Audit | 6 | 2016 | 104 | 0.370 |
Why?
|
| Adrenergic beta-Antagonists | 5 | 2018 | 252 | 0.370 |
Why?
|
| Risk Factors | 23 | 2021 | 11127 | 0.360 |
Why?
|
| Coronary Angiography | 5 | 2007 | 483 | 0.360 |
Why?
|
| Lipoproteins | 2 | 2018 | 192 | 0.360 |
Why?
|
| Infant Mortality | 1 | 2012 | 180 | 0.360 |
Why?
|
| Clinical Pharmacy Information Systems | 2 | 2009 | 20 | 0.350 |
Why?
|
| Financing, Government | 2 | 2009 | 31 | 0.350 |
Why?
|
| Budgets | 2 | 2021 | 17 | 0.350 |
Why?
|
| Socioeconomic Factors | 8 | 2021 | 920 | 0.350 |
Why?
|
| Comorbidity | 9 | 2021 | 1624 | 0.350 |
Why?
|
| Patient Admission | 4 | 2010 | 190 | 0.340 |
Why?
|
| Smoking Cessation | 2 | 2020 | 209 | 0.340 |
Why?
|
| Infant, Premature, Diseases | 1 | 2013 | 254 | 0.340 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2008 | 88 | 0.340 |
Why?
|
| Cohort Studies | 15 | 2021 | 5195 | 0.330 |
Why?
|
| Postoperative Complications | 2 | 2024 | 3167 | 0.320 |
Why?
|
| Medication Errors | 3 | 2009 | 207 | 0.320 |
Why?
|
| Internal Medicine | 4 | 2020 | 159 | 0.320 |
Why?
|
| Follow-Up Studies | 11 | 2024 | 5468 | 0.320 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 134 | 0.320 |
Why?
|
| Cholesterol, HDL | 3 | 2019 | 395 | 0.320 |
Why?
|
| Angioplasty, Balloon, Coronary | 5 | 2007 | 184 | 0.310 |
Why?
|
| Group Practice | 1 | 2009 | 12 | 0.310 |
Why?
|
| International Classification of Diseases | 1 | 2010 | 100 | 0.310 |
Why?
|
| Health Care Rationing | 2 | 2007 | 63 | 0.310 |
Why?
|
| Economics, Hospital | 1 | 2008 | 8 | 0.310 |
Why?
|
| Odds Ratio | 9 | 2020 | 1338 | 0.300 |
Why?
|
| Predictive Value of Tests | 7 | 2019 | 2297 | 0.300 |
Why?
|
| Medicine | 2 | 2010 | 107 | 0.300 |
Why?
|
| Medical Order Entry Systems | 2 | 2010 | 113 | 0.300 |
Why?
|
| Drug Costs | 2 | 2019 | 66 | 0.300 |
Why?
|
| Ezetimibe | 3 | 2019 | 98 | 0.290 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2019 | 39 | 0.290 |
Why?
|
| Prevalence | 5 | 2021 | 2669 | 0.290 |
Why?
|
| Hospital Information Systems | 1 | 2008 | 46 | 0.290 |
Why?
|
| Patient Satisfaction | 4 | 2009 | 485 | 0.280 |
Why?
|
| Time Factors | 12 | 2020 | 6585 | 0.280 |
Why?
|
| Health Status | 2 | 2007 | 412 | 0.280 |
Why?
|
| Behavioral Risk Factor Surveillance System | 6 | 2022 | 51 | 0.280 |
Why?
|
| Coronary Artery Bypass | 6 | 2010 | 532 | 0.280 |
Why?
|
| Internet | 2 | 2020 | 403 | 0.270 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2007 | 38 | 0.270 |
Why?
|
| Longitudinal Studies | 6 | 2025 | 1497 | 0.270 |
Why?
|
| Decision Theory | 1 | 2006 | 2 | 0.260 |
Why?
|
| Patient Transfer | 1 | 2007 | 110 | 0.260 |
Why?
|
| Antihypertensive Agents | 3 | 2018 | 410 | 0.260 |
Why?
|
| Child Health Services | 1 | 2007 | 88 | 0.260 |
Why?
|
| Angioplasty | 1 | 2006 | 80 | 0.250 |
Why?
|
| Brain Ischemia | 2 | 2020 | 278 | 0.250 |
Why?
|
| Hepatitis C | 1 | 2010 | 389 | 0.250 |
Why?
|
| Patient Education as Topic | 6 | 2024 | 466 | 0.240 |
Why?
|
| Community Health Centers | 1 | 2005 | 41 | 0.240 |
Why?
|
| Thrombolytic Therapy | 4 | 2016 | 211 | 0.240 |
Why?
|
| Survivorship | 5 | 2024 | 44 | 0.240 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2007 | 138 | 0.240 |
Why?
|
| Medical Errors | 2 | 2007 | 162 | 0.240 |
Why?
|
| Elective Surgical Procedures | 1 | 2006 | 168 | 0.240 |
Why?
|
| Treatment Outcome | 16 | 2021 | 13011 | 0.240 |
Why?
|
| Feedback | 2 | 2019 | 168 | 0.240 |
Why?
|
| Specialization | 1 | 2005 | 82 | 0.230 |
Why?
|
| Long-Term Care | 1 | 2005 | 73 | 0.230 |
Why?
|
| Patient Selection | 4 | 2019 | 734 | 0.230 |
Why?
|
| Faculty, Medical | 3 | 2020 | 278 | 0.220 |
Why?
|
| Surveys and Questionnaires | 9 | 2024 | 3986 | 0.220 |
Why?
|
| Medical Records | 2 | 2008 | 193 | 0.220 |
Why?
|
| Health Services Needs and Demand | 1 | 2005 | 179 | 0.220 |
Why?
|
| Thiophenes | 2 | 2014 | 72 | 0.220 |
Why?
|
| Adolescent | 11 | 2024 | 20541 | 0.220 |
Why?
|
| Algorithms | 2 | 2012 | 1734 | 0.220 |
Why?
|
| Young Adult | 7 | 2024 | 9883 | 0.210 |
Why?
|
| Prescription Drugs | 2 | 2014 | 58 | 0.210 |
Why?
|
| Clinical Decision-Making | 3 | 2020 | 296 | 0.210 |
Why?
|
| Focus Groups | 3 | 2019 | 211 | 0.210 |
Why?
|
| Hypoglycemic Agents | 4 | 2022 | 489 | 0.210 |
Why?
|
| Interferon Type I | 1 | 2024 | 115 | 0.210 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2021 | 102 | 0.200 |
Why?
|
| Neoplasms | 3 | 2020 | 3029 | 0.200 |
Why?
|
| Cardiology Service, Hospital | 1 | 2003 | 15 | 0.200 |
Why?
|
| Mass Screening | 1 | 2009 | 836 | 0.200 |
Why?
|
| Biomarkers | 11 | 2022 | 3431 | 0.200 |
Why?
|
| Risk Management | 4 | 1998 | 69 | 0.200 |
Why?
|
| Total Quality Management | 2 | 2004 | 27 | 0.200 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2022 | 6 | 0.200 |
Why?
|
| Piperazines | 2 | 2014 | 257 | 0.200 |
Why?
|
| Hospitals, Private | 2 | 1999 | 23 | 0.200 |
Why?
|
| Texas | 8 | 2019 | 3701 | 0.200 |
Why?
|
| Risk | 3 | 2012 | 835 | 0.200 |
Why?
|
| Pharmaceutical Preparations | 2 | 2022 | 91 | 0.190 |
Why?
|
| Iatrogenic Disease | 4 | 1998 | 132 | 0.190 |
Why?
|
| Blood Glucose | 2 | 2017 | 1194 | 0.190 |
Why?
|
| Discriminant Analysis | 1 | 2002 | 26 | 0.190 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2022 | 79 | 0.190 |
Why?
|
| Inpatients | 1 | 2006 | 541 | 0.190 |
Why?
|
| Software | 1 | 2007 | 735 | 0.190 |
Why?
|
| Empirical Research | 1 | 2001 | 9 | 0.190 |
Why?
|
| Fibrinolytic Agents | 3 | 2016 | 203 | 0.180 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2023 | 129 | 0.180 |
Why?
|
| Cognition | 3 | 2023 | 815 | 0.180 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2023 | 159 | 0.180 |
Why?
|
| Patient Health Questionnaire | 1 | 2021 | 18 | 0.180 |
Why?
|
| Federal Government | 1 | 2021 | 17 | 0.180 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2006 | 445 | 0.180 |
Why?
|
| Organizational Culture | 2 | 2012 | 105 | 0.180 |
Why?
|
| Hospital Departments | 1 | 2020 | 15 | 0.170 |
Why?
|
| Goals | 2 | 2011 | 134 | 0.170 |
Why?
|
| Reproducibility of Results | 4 | 2012 | 3037 | 0.170 |
Why?
|
| Rheumatic Fever | 1 | 2020 | 18 | 0.170 |
Why?
|
| Geography | 3 | 2020 | 125 | 0.170 |
Why?
|
| Qualitative Research | 3 | 2020 | 634 | 0.170 |
Why?
|
| Cluster Analysis | 2 | 2013 | 440 | 0.170 |
Why?
|
| Rivaroxaban | 1 | 2020 | 55 | 0.170 |
Why?
|
| Internship and Residency | 5 | 2011 | 1247 | 0.160 |
Why?
|
| Population Health | 1 | 2020 | 41 | 0.160 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 66 | 0.160 |
Why?
|
| Medical Staff, Hospital | 2 | 1998 | 97 | 0.160 |
Why?
|
| Aging | 2 | 2025 | 1301 | 0.160 |
Why?
|
| Pediatrics | 2 | 2020 | 1210 | 0.160 |
Why?
|
| Arthritis | 2 | 2011 | 86 | 0.160 |
Why?
|
| Infant, Newborn | 8 | 2014 | 8593 | 0.160 |
Why?
|
| Heart Failure | 4 | 2023 | 2425 | 0.160 |
Why?
|
| Population Surveillance | 1 | 2022 | 419 | 0.160 |
Why?
|
| Asthma | 1 | 2007 | 815 | 0.160 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 150 | 0.160 |
Why?
|
| Echocardiography, Stress | 1 | 2019 | 18 | 0.160 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 126 | 0.150 |
Why?
|
| Biobehavioral Sciences | 1 | 2018 | 2 | 0.150 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 89 | 0.150 |
Why?
|
| Patient Preference | 1 | 2020 | 135 | 0.150 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2019 | 58 | 0.150 |
Why?
|
| White Coat Hypertension | 1 | 2018 | 11 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 562 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 87 | 0.150 |
Why?
|
| Multivariate Analysis | 8 | 2021 | 1492 | 0.150 |
Why?
|
| Health Care Surveys | 4 | 2011 | 294 | 0.150 |
Why?
|
| Databases as Topic | 2 | 2008 | 77 | 0.150 |
Why?
|
| Physicians, Family | 1 | 1998 | 38 | 0.150 |
Why?
|
| Health Services Misuse | 1 | 1998 | 28 | 0.150 |
Why?
|
| Clinical Medicine | 1 | 1998 | 22 | 0.150 |
Why?
|
| Thinness | 1 | 2019 | 77 | 0.150 |
Why?
|
| Survivors | 2 | 2021 | 359 | 0.150 |
Why?
|
| Pandemics | 2 | 2023 | 1189 | 0.150 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2019 | 83 | 0.150 |
Why?
|
| Decision Making | 3 | 2003 | 700 | 0.140 |
Why?
|
| Interviews as Topic | 2 | 2017 | 418 | 0.140 |
Why?
|
| Hospitals, Teaching | 4 | 2002 | 114 | 0.140 |
Why?
|
| Exercise Test | 1 | 2019 | 264 | 0.140 |
Why?
|
| Transcriptome | 1 | 2025 | 1137 | 0.140 |
Why?
|
| Societies, Medical | 3 | 2015 | 778 | 0.140 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 2166 | 0.140 |
Why?
|
| Smoking | 2 | 2020 | 1136 | 0.140 |
Why?
|
| Diabetic Nephropathies | 1 | 2018 | 114 | 0.140 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 213 | 0.140 |
Why?
|
| Health Care Costs | 3 | 2021 | 407 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 389 | 0.140 |
Why?
|
| Quality of Life | 4 | 2021 | 2150 | 0.140 |
Why?
|
| Prospective Studies | 7 | 2018 | 6595 | 0.140 |
Why?
|
| Education, Medical, Continuing | 2 | 2016 | 145 | 0.130 |
Why?
|
| Research Personnel | 2 | 2012 | 135 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 271 | 0.130 |
Why?
|
| Radiology | 2 | 2009 | 124 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 326 | 0.130 |
Why?
|
| Leadership | 1 | 2019 | 244 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 404 | 0.130 |
Why?
|
| Chronic Disease | 2 | 2012 | 1255 | 0.130 |
Why?
|
| Models, Theoretical | 3 | 2016 | 398 | 0.130 |
Why?
|
| Medical Oncology | 1 | 2018 | 245 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1717 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 489 | 0.130 |
Why?
|
| Formative Feedback | 1 | 2016 | 31 | 0.130 |
Why?
|
| Mental Disorders | 2 | 2003 | 886 | 0.120 |
Why?
|
| Inservice Training | 1 | 2016 | 56 | 0.120 |
Why?
|
| Confidence Intervals | 2 | 2015 | 300 | 0.120 |
Why?
|
| Drug Utilization | 3 | 2020 | 170 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2019 | 1715 | 0.120 |
Why?
|
| Health Facilities | 2 | 2018 | 66 | 0.120 |
Why?
|
| Physician-Patient Relations | 3 | 2005 | 448 | 0.120 |
Why?
|
| Bayes Theorem | 2 | 2007 | 316 | 0.120 |
Why?
|
| Amino Acids | 1 | 2018 | 687 | 0.120 |
Why?
|
| Regression Analysis | 2 | 2007 | 826 | 0.120 |
Why?
|
| Accident Prevention | 1 | 1994 | 9 | 0.120 |
Why?
|
| Simvastatin | 1 | 2015 | 77 | 0.120 |
Why?
|
| Benchmarking | 2 | 2013 | 147 | 0.120 |
Why?
|
| Malpractice | 2 | 2007 | 59 | 0.110 |
Why?
|
| Policy Making | 2 | 2009 | 62 | 0.110 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 201 | 0.110 |
Why?
|
| Systems Analysis | 2 | 2006 | 15 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 271 | 0.110 |
Why?
|
| Incidence | 5 | 2021 | 3410 | 0.110 |
Why?
|
| Myocardial Revascularization | 2 | 2006 | 108 | 0.110 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2016 | 121 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 682 | 0.110 |
Why?
|
| Professional Review Organizations | 1 | 2013 | 1 | 0.110 |
Why?
|
| Outpatients | 1 | 2016 | 274 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 207 | 0.110 |
Why?
|
| Chi-Square Distribution | 4 | 2021 | 606 | 0.110 |
Why?
|
| Sex Distribution | 1 | 2014 | 331 | 0.110 |
Why?
|
| Systems Integration | 2 | 2004 | 28 | 0.110 |
Why?
|
| Health Maintenance Organizations | 3 | 2009 | 24 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2020 | 807 | 0.100 |
Why?
|
| Needs Assessment | 2 | 2005 | 182 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2011 | 637 | 0.100 |
Why?
|
| Random Allocation | 3 | 2011 | 448 | 0.100 |
Why?
|
| Delphi Technique | 2 | 2012 | 243 | 0.100 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 239 | 0.100 |
Why?
|
| California | 1 | 2013 | 143 | 0.100 |
Why?
|
| Self Report | 3 | 2022 | 553 | 0.100 |
Why?
|
| Triglycerides | 2 | 2012 | 614 | 0.100 |
Why?
|
| Education, Medical, Graduate | 2 | 2016 | 559 | 0.100 |
Why?
|
| Factor Analysis, Statistical | 1 | 2013 | 233 | 0.100 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2016 | 295 | 0.100 |
Why?
|
| Research Support as Topic | 2 | 2020 | 65 | 0.100 |
Why?
|
| Acute Coronary Syndrome | 1 | 2015 | 238 | 0.090 |
Why?
|
| Boston | 6 | 1998 | 123 | 0.090 |
Why?
|
| Disease Management | 2 | 2017 | 564 | 0.090 |
Why?
|
| Life Expectancy | 1 | 2012 | 60 | 0.090 |
Why?
|
| Hypotension | 1 | 2013 | 191 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2021 | 1044 | 0.090 |
Why?
|
| Sample Size | 1 | 2011 | 88 | 0.090 |
Why?
|
| Information Dissemination | 2 | 2018 | 198 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1850 | 0.090 |
Why?
|
| Neonatology | 1 | 2012 | 57 | 0.090 |
Why?
|
| Professional Practice Gaps | 2 | 2023 | 15 | 0.090 |
Why?
|
| Observer Variation | 1 | 2012 | 313 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1069 | 0.090 |
Why?
|
| Inflammation | 3 | 2024 | 1591 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2003 | 226 | 0.090 |
Why?
|
| Prognosis | 3 | 2018 | 5074 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2012 | 236 | 0.090 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 198 | 0.080 |
Why?
|
| Least-Squares Analysis | 1 | 2010 | 36 | 0.080 |
Why?
|
| Reference Values | 2 | 2011 | 742 | 0.080 |
Why?
|
| Patient Care Planning | 1 | 2011 | 134 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2010 | 3098 | 0.080 |
Why?
|
| Viremia | 1 | 2010 | 135 | 0.080 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2009 | 10 | 0.080 |
Why?
|
| Linear Models | 2 | 2010 | 722 | 0.080 |
Why?
|
| Michigan | 2 | 2020 | 52 | 0.080 |
Why?
|
| Models, Psychological | 1 | 2010 | 145 | 0.080 |
Why?
|
| Medicare Part D | 1 | 2009 | 17 | 0.080 |
Why?
|
| Travel | 1 | 2010 | 124 | 0.080 |
Why?
|
| Pharmaceutical Services | 1 | 2009 | 38 | 0.080 |
Why?
|
| Choice Behavior | 1 | 2010 | 137 | 0.080 |
Why?
|
| Delayed Diagnosis | 1 | 2010 | 135 | 0.080 |
Why?
|
| Hepacivirus | 1 | 2010 | 273 | 0.080 |
Why?
|
| Hospitals, Urban | 3 | 1998 | 99 | 0.070 |
Why?
|
| Hospital Bed Capacity, 500 and over | 3 | 1998 | 14 | 0.070 |
Why?
|
| Multiple Organ Failure | 1 | 2010 | 144 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2010 | 1159 | 0.070 |
Why?
|
| Family Practice | 2 | 2011 | 92 | 0.070 |
Why?
|
| Biomedical Technology | 1 | 2008 | 36 | 0.070 |
Why?
|
| Insurance Claim Review | 1 | 2007 | 27 | 0.070 |
Why?
|
| Cost Control | 1 | 2007 | 24 | 0.070 |
Why?
|
| Hospitalization | 2 | 2007 | 1900 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2010 | 254 | 0.070 |
Why?
|
| Models, Econometric | 1 | 2007 | 9 | 0.070 |
Why?
|
| Ohio | 1 | 2007 | 87 | 0.070 |
Why?
|
| Estrogen Replacement Therapy | 2 | 1998 | 51 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2021 | 3655 | 0.070 |
Why?
|
| Probability | 1 | 2007 | 335 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 401 | 0.070 |
Why?
|
| Obesity | 1 | 2019 | 2433 | 0.070 |
Why?
|
| Cost of Illness | 2 | 2006 | 276 | 0.070 |
Why?
|
| Health Policy | 1 | 2009 | 233 | 0.070 |
Why?
|
| Aviation | 1 | 2006 | 5 | 0.060 |
Why?
|
| Statistical Distributions | 1 | 2006 | 3 | 0.060 |
Why?
|
| Women's Health | 1 | 2008 | 150 | 0.060 |
Why?
|
| Ergonomics | 1 | 2006 | 24 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2006 | 152 | 0.060 |
Why?
|
| Health Education | 1 | 2008 | 228 | 0.060 |
Why?
|
| Cardiac Care Facilities | 1 | 2006 | 10 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 373 | 0.060 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2010 | 485 | 0.060 |
Why?
|
| Economics, Medical | 1 | 2005 | 8 | 0.060 |
Why?
|
| Nephrology | 1 | 2007 | 153 | 0.060 |
Why?
|
| Angina, Unstable | 1 | 2006 | 55 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1735 | 0.060 |
Why?
|
| Insurance, Health | 1 | 2006 | 145 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 1388 | 0.060 |
Why?
|
| Cross-Cultural Comparison | 1 | 2005 | 59 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 1998 | 285 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2010 | 824 | 0.060 |
Why?
|
| Rumination, Cognitive | 1 | 2024 | 2 | 0.060 |
Why?
|
| Recovery of Function | 1 | 2007 | 469 | 0.060 |
Why?
|
| Utilization Review | 1 | 2004 | 41 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 1199 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2025 | 118 | 0.060 |
Why?
|
| Infant, Premature | 1 | 2010 | 858 | 0.050 |
Why?
|
| Staff Development | 1 | 2004 | 46 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 1153 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2007 | 817 | 0.050 |
Why?
|
| Psychometrics | 2 | 2012 | 689 | 0.050 |
Why?
|
| Regional Medical Programs | 1 | 2003 | 17 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1974 | 0.050 |
Why?
|
| Virginia | 1 | 2003 | 20 | 0.050 |
Why?
|
| Cellular Senescence | 1 | 2025 | 201 | 0.050 |
Why?
|
| Morbidity | 1 | 2024 | 256 | 0.050 |
Why?
|
| Awards and Prizes | 1 | 2004 | 72 | 0.050 |
Why?
|
| Patient Discharge | 3 | 2010 | 519 | 0.050 |
Why?
|
| General Surgery | 1 | 2005 | 217 | 0.050 |
Why?
|
| Models, Organizational | 1 | 2003 | 44 | 0.050 |
Why?
|
| Attitude to Computers | 1 | 2003 | 48 | 0.050 |
Why?
|
| Career Choice | 1 | 2004 | 162 | 0.050 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2003 | 67 | 0.050 |
Why?
|
| Race Relations | 1 | 2002 | 1 | 0.050 |
Why?
|
| Bias | 1 | 2003 | 147 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2007 | 1005 | 0.050 |
Why?
|
| Pyridones | 1 | 2023 | 125 | 0.050 |
Why?
|
| Personnel, Hospital | 2 | 2012 | 34 | 0.050 |
Why?
|
| Costs and Cost Analysis | 3 | 2017 | 165 | 0.050 |
Why?
|
| Occupational Health | 2 | 2012 | 48 | 0.050 |
Why?
|
| DNA Damage | 1 | 2025 | 545 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2022 | 221 | 0.040 |
Why?
|
| Survival Rate | 1 | 2006 | 2217 | 0.040 |
Why?
|
| Matched-Pair Analysis | 1 | 2000 | 33 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 549 | 0.040 |
Why?
|
| Minority Groups | 1 | 2003 | 255 | 0.040 |
Why?
|
| Thinking | 1 | 2021 | 35 | 0.040 |
Why?
|
| Epidemiology | 1 | 2020 | 10 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2022 | 144 | 0.040 |
Why?
|
| Nursing | 1 | 2020 | 11 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 108 | 0.040 |
Why?
|
| Hotlines | 1 | 2020 | 1 | 0.040 |
Why?
|
| RNA | 1 | 2024 | 605 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 450 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 914 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2022 | 538 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 51 | 0.040 |
Why?
|
| Hospitals, Low-Volume | 1 | 2019 | 33 | 0.040 |
Why?
|
| Hospitals, High-Volume | 1 | 2019 | 38 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 636 | 0.040 |
Why?
|
| Cigarette Smoking | 1 | 2020 | 80 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2022 | 702 | 0.040 |
Why?
|
| Personnel Turnover | 1 | 2019 | 9 | 0.040 |
Why?
|
| Social Networking | 1 | 2019 | 19 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2020 | 116 | 0.040 |
Why?
|
| Educational Status | 1 | 2020 | 298 | 0.040 |
Why?
|
| Medical Informatics | 1 | 2020 | 112 | 0.040 |
Why?
|
| Models, Economic | 1 | 2019 | 55 | 0.040 |
Why?
|
| New England | 1 | 1998 | 13 | 0.040 |
Why?
|
| Research | 1 | 2020 | 273 | 0.040 |
Why?
|
| Mastectomy | 1 | 2018 | 81 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 333 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 168 | 0.040 |
Why?
|
| Proprotein Convertase 9 | 1 | 2019 | 82 | 0.040 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 1998 | 5 | 0.040 |
Why?
|
| Sentinel Surveillance | 1 | 1998 | 24 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 1998 | 149 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 291 | 0.040 |
Why?
|
| APACHE | 1 | 1998 | 57 | 0.040 |
Why?
|
| Noncommunicable Diseases | 1 | 2018 | 18 | 0.040 |
Why?
|
| Prostatic Hyperplasia | 1 | 1998 | 118 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2018 | 148 | 0.040 |
Why?
|
| Executive Function | 1 | 2018 | 124 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 925 | 0.030 |
Why?
|
| Osteoporosis | 1 | 1998 | 140 | 0.030 |
Why?
|
| Emergencies | 1 | 1998 | 185 | 0.030 |
Why?
|
| Documentation | 1 | 2018 | 122 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2002 | 522 | 0.030 |
Why?
|
| Physician's Role | 1 | 1998 | 171 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 305 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2020 | 508 | 0.030 |
Why?
|
| Hospital Charges | 1 | 1997 | 63 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2018 | 187 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 117 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 727 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 1998 | 387 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 716 | 0.030 |
Why?
|
| Stroke | 2 | 2020 | 1074 | 0.030 |
Why?
|
| Mammography | 1 | 1996 | 133 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 149 | 0.030 |
Why?
|
| Medication Systems, Hospital | 1 | 1995 | 46 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 190 | 0.030 |
Why?
|
| Depressive Disorder, Major | 1 | 2021 | 472 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1313 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 987 | 0.030 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 384 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 395 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 1994 | 42 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2016 | 134 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2240 | 0.030 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2014 | 24 | 0.030 |
Why?
|
| Anxiety | 1 | 2021 | 991 | 0.030 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2014 | 47 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 1994 | 261 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1596 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 500 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 432 | 0.030 |
Why?
|
| Cross Infection | 1 | 2016 | 344 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 554 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2016 | 604 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 2011 | 74 | 0.020 |
Why?
|
| Job Satisfaction | 1 | 2011 | 92 | 0.020 |
Why?
|
| Length of Stay | 1 | 1997 | 1388 | 0.020 |
Why?
|
| Child | 2 | 2010 | 25780 | 0.020 |
Why?
|
| Vital Signs | 1 | 2010 | 22 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 1215 | 0.020 |
Why?
|
| Heart Valves | 1 | 2010 | 54 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2009 | 122 | 0.020 |
Why?
|
| Acute Disease | 2 | 2006 | 1191 | 0.020 |
Why?
|
| Endocrinology | 1 | 2011 | 135 | 0.020 |
Why?
|
| Medicare Part C | 1 | 2009 | 39 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 454 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 563 | 0.020 |
Why?
|
| Comprehension | 1 | 2008 | 81 | 0.020 |
Why?
|
| Insurance, Liability | 1 | 2007 | 7 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2010 | 219 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 137 | 0.020 |
Why?
|
| Weight Gain | 1 | 2010 | 412 | 0.020 |
Why?
|
| Neck Pain | 1 | 2006 | 19 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2011 | 601 | 0.020 |
Why?
|
| Spinal Cord Compression | 1 | 2006 | 33 | 0.020 |
Why?
|
| HIV Infections | 1 | 1998 | 2072 | 0.020 |
Why?
|
| Drug Therapy | 2 | 1997 | 93 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2009 | 413 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2006 | 195 | 0.020 |
Why?
|
| Accreditation | 1 | 2005 | 93 | 0.010 |
Why?
|
| Training Support | 1 | 2004 | 19 | 0.010 |
Why?
|
| Hospitals, University | 2 | 1995 | 106 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2005 | 203 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 139 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2010 | 888 | 0.010 |
Why?
|
| Syndrome | 1 | 2006 | 1159 | 0.010 |
Why?
|
| Mentors | 1 | 2004 | 160 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2002 | 57 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 1783 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2004 | 315 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2005 | 559 | 0.010 |
Why?
|
| Pharmacies | 1 | 1998 | 15 | 0.010 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 1998 | 51 | 0.010 |
Why?
|
| Patient Readmission | 1 | 1995 | 418 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 1995 | 538 | 0.010 |
Why?
|